{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:24:12Z","timestamp":1761488652732,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T00:00:00Z","timestamp":1299715200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Mass Spectrom."],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A new and reliable mass spectrometric method using an isotope dilution method in combination with matrix\u2010assisted laser desorption\/ionization\u2010triple quadrupole tandem mass spectrometry (ID\u2010MALDI\u2010QqQ\u2010MS\/MS) has been developed and validated for the determination of concentrations of the antiretroviral drug tenofovir (TNV) in plasma from HIV\u2010infected adults. The advantage of this new method is that (1) the method is ultrafast and (2) can be applied for high\u2010throughput measurement of TNV in plasma. The method is based on a simple plasma deproteinization step in combination with the use of [adenine\u2010<jats:sup>13<\/jats:sup>C<jats:sub>5<\/jats:sub>]\u2010TNV as the internal standard. TNV and [adenine\u2010<jats:sup>13<\/jats:sup>C<jats:sub>5<\/jats:sub>]\u2010TNV were monitored by multiple reaction monitoring using the transition <jats:italic>m<\/jats:italic>\/<jats:italic>z<\/jats:italic> 288.0 \u2192 176.2 and <jats:italic>m<\/jats:italic>\/<jats:italic>z<\/jats:italic> 293.2 \u2192 181.2 for TNV and [adenine\u2010<jats:sup>13<\/jats:sup>C<jats:sub>5<\/jats:sub>]\u2010TNV, respectively. The method was validated according to the most recent FDA guidelines for the development and validation of (new) bio\u2010analytical assays. Validated method parameters were: linearity, accuracy, precision and stability of the method. The lowest limit of quantification was 0.10 \u00b5mol\/l, whereas the limit of detection determined at a signal\u2010to\u2010noise ratio (<jats:italic>S<\/jats:italic>\/<jats:italic>N<\/jats:italic> = 3:1) in pooled drug free human control plasma was 0.04 \u00b5mol\/l. The validated method was successfully applied and tested for its clinical feasibility by the analysis of plasma samples from selected HIV\u2010infected adults receiving the prodrug tenofovir disoproxil fumarate. Observed plasma TNV concentrations ranged between 0.11 and 0.76 \u00b5mol\/l and measured plasma TNV concentrations were within the therapeutically relevant concentration range. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/jms.1897","type":"journal-article","created":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T01:05:48Z","timestamp":1299719148000},"page":"282-289","source":"Crossref","is-referenced-by-count":17,"title":["Determination of the antiretroviral drug tenofovir in plasma from HIV\u2010infected adults by ultrafast isotope dilution MALDI\u2010triple quadrupole tandem mass spectrometry"],"prefix":"10.1002","volume":"46","author":[{"given":"Roland J. W.","family":"Meesters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J. A.","family":"van Kampen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel D.","family":"Scheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marchina E.","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob A.","family":"Gruters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo M.","family":"Luider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443090-00003"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80058-3"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00333-7"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.06.019"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00225-3"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(99)00447-8"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.05.029"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.10.015"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac060436i"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mas.20268"},{"volume-title":"Center for Drug Evaluation and Research (CDER) Guidance for Industry: Bioanalytical Method Validation","year":"2001","author":"CDER","key":"e_1_2_6_13_2"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-010-4192-8"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-010-3952-9"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011409"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.07.009"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.1192"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.2006"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1087057108326143"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac7016234"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.02.010"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.01.009"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac800218a"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00075197-200103000-00003"}],"container-title":["Journal of Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjms.1897","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jms.1897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:52:38Z","timestamp":1760626358000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jms.1897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1002\/jms.1897"],"URL":"https:\/\/doi.org\/10.1002\/jms.1897","archive":["Portico"],"relation":{},"ISSN":["1076-5174","1096-9888"],"issn-type":[{"type":"print","value":"1076-5174"},{"type":"electronic","value":"1096-9888"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}